Browser storage is unavailable. Keep this page open and export your collection before leaving.

Nephrogen
Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies. Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expe
Overview
Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies.
Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas, and has attracted non-dilutive funding from seven major pharmaceutical companies including Merck KGaA, Novartis, and Bristol Myers Squibb.
Founders & team
No directly sourced team information is available yet.
Founded 2022 · Source
News & product activity
Sources & observations
Maturity: Not assessed · 2 of 6 areas documented
Source-based assessment · automated evidence rules
The retained text does not establish product availability or customer use.
Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.
- Product overviewSource description Checked 2026-11-08
- Product visualsNot documented
- Founders & originsNot documented
- Business model & pricingNot documented
- Funding & ownershipNot documented
- Dated milestonesDated source activity: 2020 Q3 (quarter only)





